Seeking Alpha

FDA approves NeuroMetrix pain device

  • The FDA grants 510(k) clearance to NeuroMetrix's (NURO) Sensus chronic pain treatment device. The wearable product delivers non-invasive electrical stimulation to sensory nerves as a method to relieve pain. It can be worn day and night and will be available over-the-counter without a prescription.
  • NURO shares are up 28% premarket on light volume.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: